ASCO 2018: Adjuvant Therapy Has No Compelling Benefit in Treatment of High-Risk Renal Cell Cancer
Adjuvant treatment with VEGF-TKIs may also carry greater risk of toxicity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.